Ilyang Pharmaceutical Co.,Ltd Cash Flow Quality Index
Ilyang Pharmaceutical Co.,Ltd cash flow quality index. Ilyang Pharmaceutical Co.,Ltd (007575) has a Cash Flow Quality Index of 1.58x as of March 2026. Operating cash flow of ₩26.51 Billion exceeds net income of ₩16.80 Billion, indicating high earnings quality where cash backs reported profits. See financial agility of Ilyang Pharmaceutical Co.,Ltd to measure the company's free cash flow as a share of total liabilities.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of Ilyang Pharmaceutical Co.,Ltd (2015–2025)
Cash flow quality index of Ilyang Pharmaceutical Co.,Ltd from 2015 to 2025. Historical Cash Flow Quality Index for Ilyang Pharmaceutical Co.,Ltd across 9 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore Ilyang Pharmaceutical Co.,Ltd cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Ilyang Pharmaceutical Co.,Ltd Cash Flow Quality Index by Year (2015–2025)
Ilyang Pharmaceutical Co.,Ltd cash flow quality index by year from 2015 to 2025. Year-by-year earnings quality comparison for Ilyang Pharmaceutical Co.,Ltd. For the full cash flow conversion analysis, see Ilyang Pharmaceutical Co.,Ltd cash flow conversion.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 1.74x | ₩12.04 Billion | ₩6.90 Billion | ▲ +180.5% |
| 2024 | 0.62x | ₩5.61 Billion | ₩9.03 Billion | ▼ -60.0% |
| 2022 | 1.56x | ₩29.94 Billion | ₩19.24 Billion | ▼ -66.6% |
| 2021 | 4.66x | ₩67.02 Billion | ₩14.38 Billion | ▼ -11.8% |
| 2020 | 5.28x | ₩57.48 Billion | ₩10.88 Billion | ▲ +45.8% |
| 2019 | 3.62x | ₩36.19 Billion | ₩9.98 Billion | ▼ -24.4% |
| 2017 | 4.79x | ₩30.03 Billion | ₩6.26 Billion | ▲ +4.9% |
| 2016 | 4.57x | ₩26.98 Billion | ₩5.91 Billion | ▼ -50.0% |
| 2015 | 9.13x | ₩40.27 Billion | ₩4.41 Billion | — |